Home / Science / Gila Monster Venom: A Painful Path to Miraculous Medicine
Gila Monster Venom: A Painful Path to Miraculous Medicine
11 Nov
Summary
- Gila monster venom led to GLP-1 drugs for diabetes and obesity.
- Dr. John Eng discovered a peptide in venom similar to human GLP-1.
- These drugs have reshaped the pharmaceutical industry since 2026.
Native to the southwestern deserts of North America, the Gila monster is the United States' only venomous lizard. Its striking appearance and painful bite, once feared by settlers, belied its incredible medicinal potential. Early scientists, like Dr. George Goodfellow, endured painful bites in 1891 to study the venom's effects.
In 1990, Dr. John Eng identified Exendin-4 in the Gila monster's venom, a peptide structurally similar to the human hormone GLP-1. This discovery was groundbreaking, as Exendin-4 demonstrated a longer duration of action, offering a novel approach to diabetes treatment.
Further research revealed that Exendin-4 and its derivatives have wider benefits, including appetite suppression, reduced inflammation, and cardiovascular protection. This led to the development of semaglutide medications like Ozempic and Wegovy.
By the first six months of 2026, Ozempic alone had generated approximately $9.1 billion USD, with 12% of American adults currently using GLP-1 medications. These drugs, inspired by the Gila monster's venom, have become a pharmaceutical sensation.
